---
slug: semaglutide
title: "semaglutide"
kind: standard
status: published
hash: f5a5a57533c5d5f11c36ac853524eb7d77cb047a20961f1693e7050dd6228567
created: 2026-06-29T17:01:15.697Z
updated: 2026-10-08T11:49:46.253Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# semaglutide

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T17:01:16.648Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity](https://pubmed.ncbi.nlm.nih.gov/40934115/) — “Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).” (sha256 0d1a7ed9734b3e39)
2. [Once-weekly semaglutide 7·2 mg in adults with obesity](https://pubmed.ncbi.nlm.nih.gov/40961952/) — “Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.” (sha256 dd0a7a4d830e8953)
3. [Semaglutide in Adults with Type 1 Diabetes and Obesity](https://pubmed.ncbi.nlm.nih.gov/40550013/) — “Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.” (sha256 cfabad54ee1f8aa4)
4. [The expanding role of semaglutide: beyond glycemic control](https://pubmed.ncbi.nlm.nih.gov/40620322/) — “This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.” (sha256 5488b614069df44d)
5. [Phase III Clinical Study on the Efficacy and Safety of Semaglutide](https://clinicaltrials.gov/study/NCT07046273) — “A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...” (sha256 4e58cc6ce72cecb9)